

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	iii
ABSTRACT (ENGLISH)	vi
ABSTRACT (THAI)	x
TABLE OF CONTENTS	xiii
LIST OF TABLES	xxv
LIST OF FIGURES	xxviii
ABBREVIATIONS	xxxix
CHAPTER 1 GENERAL INTRODUCTION	1
CHAPTER 2 LITERATURE REVIEW	4
1. Skin morphology	4
2. Traditional carrier systems	5
2.1. Liposome	6
2.2. Emulsion	6
2.3. Polymeric nanoparticles	7
3. Innovative carrier systems	8
3.1. Lipid nanoparticles	8
4. Technologies of production	18
4.1. Microemulsion based technique	18
4.2. High pressure homogenizer	19

4.3. Ultra-sonication	20
4.4. The solvent emulsification evaporation method	20
4.5. The solvent displacement method	21
4.6. The emulsification diffusion method	21
4.7. The phase inversion based method	22
5. Antioxidant	22
5.1. Lycopene	23
6. Lipids	31
6.1. Solid lipids	31
6.1.1. Orange wax	31
6.1.2. Cholesterol	33
6.1.3. <i>Mangifera indica</i> seeds butter	35
6.1.4. Beeswax	36
6.2. Liquid lipids	37
6.2.1. Rice bran oil	37
6.2.2. Pomegranate seeds oil	39
6.3. Emulsifiers	41
6.3.1. Eumulgin™ SG	41
6.3.2. Tegocare™ 450	42
6.3.3. Inutec™ SP1	42
6.3.4. Plantacare™ 1200	44
6.3.5. Sucrose ester emulsifiers	45
6.3.6. Polysorbate 80	46

6.3.7. Dermofeel™ SL	47
CHAPTER 3 MATERIALS AND METHODS	48
1. Materials	48
1.1. Solid lipids	48
1.2. Liquid lipids	48
1.3. Active compound	48
1.4. Surfactants	48
1.5. Solvents	49
1.6. Antioxidant tests	49
1.7. Zeta potential measurement	50
1.8. Silanized solution	50
1.9. Solubility test	50
1.10. Cream base	51
2. Method	52
<u>Part I</u> Preformulation study of lycopene and carriers	52
1. Preliminary physicochemical properties of lycopene	52
1.1. Lycopene identification	52
1.1.1. UV-visible (UV/Vis) analysis	52
1.1.2. HPLC analysis	52
1.2. Solubility	52
1.3. Thermal analysis	53
1.4. Crystalline characterization	53
1.5. Morphology	53

1.5.1. Light microscopy and polarized light microscopy	54
1.6. Biological action (antioxidant activities)	54
1.6.1. ABTS assay	54
1.6.2. DPPH assay	54
1.7. Stability of lycopene	55
1.7.1. Crystalline characterization	55
2. Preliminary physicochemical properties of carriers (solid lipids and liquid lipids)	55
2.1. Physicochemical properties of solid lipids	55
2.1.1. Morphology	55
2.1.2. Thermal analysis	55
2.1.3. Crystalline characterization	56
2.2. Physicochemical properties of liquid lipids	56
2.2.1. Thermal analysis	56
2.2.2. Biological action (antioxidant activities)	56
<u>Part II</u> Optimization of formulations	56
1. Effect of surfactant	56
1.1. Preparation of lipid nanoparticles	56
1.2. Effect of surfactant on contact angle	58
1.2.1. Goniometric measurement	58
1.3. Effect of surfactant on the particle size	58
1.3.1. Particle size analysis	59
1.4. Effect of surfactant on the physical stability of the	59

NLC	
1.4.1. Particle size analysis	59
1.4.2. Zeta potentiometry	59
1.5. Chemical stability of the lycopene	60
1.5.1. UV/Vis spectrophotometry	60
2. Effect of different solid lipids	60
2.1. Preparation of lipid nanoparticles	60
2.2. Particle size analysis	60
2.2.1. Photon correlation spectrophotometry	60
2.2.2. Low angle static light scattering	60
2.3. Zeta potentiometry	61
3. Effect of the amount of cycle and pressure	61
3.1. Particle size analysis	61
4. Effect of different liquid lipids	61
4.1. Particle size analysis	62
5. Comparison of NLC system <i>versus</i> NE system	62
5.1. The effect of lipid nanoparticle formulations on the particle size	62
5.1.1. Particle size analysis	63
5.2. Entrapment efficiency	63
5.3. Biological action (antioxidant activities)	63
5.4. Stability test	63
5.4.1. Particle size analysis	63

5.4.2. Zeta potentiometry	63
6. Effect of surfactant on NLC stability	64
6.1. Steric effect	64
6.1.1. Particle size analysis	64
6.2. Electrostatic effect	64
6.2.1. Particle size analysis	64
Part III Preparation and physicochemical study of lycopene-loaded NLC	64
1. Development of skin friendly lycopene-loaded NLC	64
1.1. Morphology and re-crystallize of lipid matrix	64
1.2. Effect of lipid combination	65
1.2.1. Thermal analysis	65
1.3. Preparation and characterization of the investigated formulations	65
1.3.1. Preparation of lipid nanoparticle	65
1.3.1.1. Preparation of lipid nanoparticle	65
1.3.2. Particle size analysis	65
1.3.3. Electric conductivity measurements	65
1.4. Effect of lipid on the state of the internal phase	65
1.4.1. Thermal analysis	65
1.5. Effect of rice bran oil and cholesterol on the state of the internal phase	65
1.5.1. Thermal analysis	65

1.6. Effect of rice bran oil and cholesterol on particle size of the internal phase	66
1.6.1. Particle size analysis	66
1.7. Effect of rice bran oil and cholesterol on zeta potential of the internal phase	66
1.7.1. Zeta potentiometry	66
1.8. Stability	66
1.8.1. Particle size analysis	66
1.8.2. Zeta potentiometry	66
1.8.3. Stability profile of lycopene	66
1.9. Occlusion property	66
2. The investigation on crystallization behavior of lycopene-loaded NLC	67
2.1. Thermal analysis	67
2.2. Crystalline characterization	67
2.2.1. WAXS	67
2.2.2. Electron diffraction mode of TEM analysis	67
2.3. The bright field cryo-TEM analysis	67

Part IV Effect of lycopene concentration on lycopene-loaded NLC 68

1. Effect on the particle size and ZP	68
1.1. Preparation of lipid nanoparticle	68
1.1.1. Particle size analysis	69

1.1.2. Zeta potentiometry	69
2. Entrapment efficiency	69
3. The <i>in vitro</i> release study	69
3.1. Membrane free release	69
3.2. Release from membrane	70
4. Occlusive property	70
5. Biological action (antioxidant activities)	70
6. Stability test	70
6.1. Particle size analysis	70
6.2. Zeta potentiometry	70
6.3. Stability profile of lycopene	70
<u>Part V</u> Preparation and evaluation of topical dosage forms	71
1. Preparation of topical dosage form	71
2. Occlusion property	71
3. Stability test	71
3.1. Stability profile of lycopene	71
4. Antioxidant activities	71
5. Statistical analysis	71

CHAPTER 4 RESULTS AND DISCUSSION 72

Part I Preformulation study of lycopene and carriers 72

1. Preliminary physicochemical properties of lycopene	72
1.1. Lycopene identification	72
1.1.1. UV-visible (UV/Vis) analysis	72

1.1.2. HPLC analysis	73
1.2. Solubility	75
1.3. Thermal analysis	78
1.4. Crystalline characterization	79
1.5. Morphology	80
1.6. Biological action (antioxidant activities)	81
1.6.1. ABTS assay	81
1.6.2. DPPH assay	83
1.7. Stability of lycopene	84
2. Preliminary physicochemical properties of carriers (solid lipids and liquid lipids)	86
2.1. Physicochemical properties of solid lipids	86
2.1.1. Orange wax	86
2.1.2. Mango butter	90
2.1.3. Beeswax	93
2.2. Physicochemical properties of liquid lipids	96
2.2.1. Thermal analysis	96
2.2.2. Antioxidant activities	97
2.2.2.1. ABTS assay	97
2.2.2.2. DPPH assay	99
Part II Optimization of formulations	101
1. Effect of surfactant	101
1.1. Effect of surfactant on contact angle	101

1.2. Effect of surfactant on the particle size	103
1.3. Effect of surfactant on the physical stability of the NLC	105
1.4. Chemical stability of the lycopene	108
2. Effect of different solid lipids	110
3. Effect of the amount of cycle and pressure	112
4. Effect of different liquid lipids	115
5. Comparison of NLC system <i>versus</i> NE system	119
5.1. The effect of lipid nanoparticle formulations on the particle size	119
5.2. Entrapment efficiency	120
5.3. Antioxidant activities	121
5.3.1. ABTS assay	121
5.3.2. DPPH assay	122
5.4. Stability test	124
6. Effect of surfactant on NLC stability	125
6.1. Steric effect	125
6.2. Electrostatic effect	127
<u>Part III</u> Preparation and physicochemical study of lycopene-loaded NLC	130
1. Development of skin friendly lycopene-loaded NLC	132
1.1. Morphology and re-crystalline of lipid matrix	132
1.2. Effect of lipid combination	136

1.3. Preparation and characterization of the investigated formulations	139
1.4. Effect of lipid on the state of the internal phase	143
1.5. Effect of rice bran oil and cholesterol on the state of the internal phase	144
1.6. Effect of rice bran oil and cholesterol on particle size of the internal phase	145
1.7. Effect of rice bran oil and cholesterol on zeta potential of the internal phase	148
1.8. Stability	148
1.9. Occlusive property	153
2. The investigation on crystallization behavior of lycopene-loaded NLC	155
2.1. Thermal analysis	157
2.2. Crystalline characterization	160
2.3. Electron diffraction mode of TEM analysis	161
2.4. The bright field cryo-TEM analysis	164
<u>Part IV</u> Effect of lycopene concentration on lycopene-loaded NLC	166
1. Effect on the particle size and ZP	166
2. Entrapment efficiency	168
3. The <i>in vitro</i> release study	169
3.1. Membrane free release	169
3.2. Release from membrane	170

4. Occlusive property	172
5. Biological action (antioxidant activities)	173
5.1. ABTS assay	173
5.2. DPPH assay	174
6. Stability test	175
<u>Part V</u> Preparation and evaluation of topical dosage forms	179
1. Occlusive property	182
2. Stability test	184
3. Antioxidant activities	186
3.1. ABTS assay	186
3.2. DPPH assay	186
CHAPTER 5 CONCLUSION	188
REFERENCES	192
APPENDICES	223
APPENDIX A	224
APPENDIX B	230
APPENDIX C	232
CURRICULUM VITAE	233
LIST OF PUBLICATIONS	234

LIST OF TABLES

Table		Page
2-1	Overview of NLC-based cosmetic products introduced to the market since October 2005 onward.	13
2-2	Lycopene levels in human tissues.	24
2-3	Comparison of antioxidant activities of carotenoids: singlet oxygen quenching.	29
2-4	Primary chemical composition of orange wax by percent.	32
2-5	Skin lipid composition compared to orange wax chemistry.	32
2-6	The fatty acid composition and their percentage of rice bran oil.	39
2-7	Summary of composition and HLB of sucrose ester emulsifiers.	45
3-1	The properties of selected surfactants.	57
3-2	The percentage of compositions used in the NLC and NE formulations.	62
4-1-1	The resulted suitable HPLC condition.	75
4-1-2	Solubility of lycopene in melted solid lipids at room temperature after heating at 80°C.	76
4-1-3	Solubility of lycopene in organic solvents at room temperature and in liquid lipids and surfactants at room temperature after heating at 80°C.	76

4-1-4	Thermal events observed in DSC analysis of orange wax shown in Figure 4-1-17.	89
4-1-5	Thermal events observed in DSC analysis of beeswax shown in Figure 4-1-26.	95
4-1-6	Summarization of TEAC values ($\mu\text{M}/\text{mg}$) of different liquid lipids and liquid lipids contain the equal specific amount of lycopene.	98
4-1-7	Summarization of IC_{50} values by ABTS assay of different liquid lipids and liquid lipids contain the equal specific amount of lycopene.	98
4-1-8	Summarization of IC_{50} values by DPPH assay of different liquid lipids and liquid lipids contain the equal specific amount of lycopene.	100
4-2-1	TEAC values of NLC and NE samples by ABTS radical method.	122
4-2-2	IC_{50} values of NLC and NE samples by DPPH radical method.	123
4-2-3	Physical properties of Poloxamer TM surfactants.	126
4-2-4	Stability on particle size (PCS and LD (0.99) diameters) and Pdl of formulations using Poloxamer TM 188 and Poloxamer TM 407.	127
4-2-5	Stability on particle size (PCS and LD (0.99) diameters) and Pdl of formulations using Dermofeel TM SL and Eumulgin TM SG.	129
4-3-1	Composition of ingredients used in the lipid nanoparticle bases.	140
4-3-2	Composition of ingredients used in lycopene loaded lipid nanoparticle formulations.	142
4-3-3	Conductivity values of lycopene loaded lipid nanoparticle formulations.	143

4-3-4	The DSC parameters of orange wax, NE, SLN, and NLC formulations.	159
4-4-1	PCS diameters, PDI and ZP values of NLC samples on freshly prepared (day 0) stored at room temperature.	168
4-4-2	TEAC values of NLC samples by ABTS radical method.	174
4-4-3	IC ₅₀ values of NLC samples by DPPH radical method.	175
4-4-4	PCS diameters of NLC samples over a period of 120 days stored at 4°C, 30°C and 40°C.	176
4-4-5	PDI values of NLC samples over a period of 120 days stored at 4°C, 30°C and 40°C.	176
4-4-6	ZP values of NLC samples over a period of 120 days stored at 4°C, 30°C and 40°C.	177
4-5-1	The amount of ingredients (%w/w) in 7 semisolid cream formulations containing NLC dispersion.	180
4-5-2	The texture of 7 semisolid cream formulations containing NLC.	181

LIST OF FIGURES

Figure		Page
2-1	The three layers of the skin (http://www.enchantedlearning.com/subjects/anatomy/skin/ , available online 12/12/2012).	4
2-2	The layers of the epidermis (modified after http://dermatology.about.com/od/anatomy/ss/epidermis.htm , available online 12/12/2012).	5
2-3	The controlled occlusion effect of lipid nanoparticles is a function of the particle size (left: at identical lipid concentration, one big particle gives many small particles) and a function of increasing particle number (right: increase of lipid concentration, at a given particle size).	9
2-4	Development of traditional carriers to lipid nanoparticles.	10
2-5	Situations on damaged skin.	11
2-6	Propose mechanisms of lipid nanoparticles (SLN and NLC) in repairing the damaged skin.	11
2-7	All-trans lycopene.	25
2-8	Structures of most common lycopene isomers.	27
2-9	The chemical structure of cholesterol.	35

2-10	The structure of the rice kernel. The bran fraction, which includes the germ or embryo in most commercial milling operations, represents only about 8% of paddy weight but contains about three-fourths of the total oil (http://www.ricebranoil.info/index.html) (available online 15/10/2011).	38
2-11	The chemical structure of punicic acid.	41
2-12	The chemical structure of hydrophobized inulin.	44
4-1-1	UV/Vis spectrum of lycopene standard solution.	73
4-1-2	Calibration curve of lycopene by UV/Vis analysis.	73
4-1-3	Calibration curve of lycopene by HPLC analysis.	74
4-1-4	The HPLC chromatogram of standard lycopene solution at 1 $\mu\text{g/mL}$.	74
4-1-5	DSC heating (1) and cooling (2) curves of lycopene compound.	79
4-1-6	WAXS pattern of lycopene powder.	79
4-1-7	Physical appearance of lycopene powder.	80
4-1-8	LM picture (A) and PLM picture (B) of lycopene powder suspended in rice bran oil with magnification of 100x10 folds.	80
4-1-9	Formation of ABTS^{++} (Moon and Shibamoto, 2009) with some modifications.	81
4-1-10	%Inhibition of standard Trolox TM solution which varies the concentrations and reaction time.	82
4-1-11	Standard calibration curve of Trolox TM solution at concentration of 2-39 μM at reaction time of 3 min.	83

4-1-12	Mechanism of action by antioxidants on DPPH radical in DPPH assay (Moon and Shibamoto, 2009) with some modifications.	84
4-1-13	Outer appearance of original lycopene powder (A) and degraded lycopene powder (B) under exposed to light and oxygen after 7 days at room temperature.	85
4-1-14	WAXS pattern of degraded lycopene powder.	86
4-1-15	Physical appearance of orange wax.	87
4-1-16	LM picture (A) and PLM picture (B) of orange wax with magnification of 100x10 folds.	87
4-1-17	DSC 1 st heating (1), 1 st cooling (2), 2 nd heating (3) and 2 nd cooling (4) curves of orange wax.	88
4-1-18	WAXS pattern of orange wax.	89
4-1-19	Physical appearance of mango butter.	90
4-1-20	LM picture (A) and PLM picture (B) of mango butter with magnification of 100x10 folds.	90
4-1-21	LM picture (A) and PLM picture (B) of the mixture of mango butter and lycopene with magnification of 100x10 folds.	91
4-1-22	DSC 1 st heating (1), 1 st cooling (2), 2 nd heating (3) and 2 nd cooling (4) curves for mango butter (I-VI are existing polymorph forms).	92
4-1-23	WAXS pattern of mango butter.	93
4-1-24	LM picture (A) and PLM picture (B) of the mixture of beeswax with magnification of 100x10 folds.	93

4-1-25	LM picture (A) and PLM picture (B) of the mixture of beeswax and lycopene with magnification of 100x10 folds.	94
4-1-26	DSC 1 st heating (1), 1 st cooling (2), 2 nd heating (3) and 2 nd cooling (4) curves of beeswax.	95
4-1-27	WAXS pattern of beeswax.	96
4-1-28	DSC thermograms of the mixtures of orange wax (90%) and different liquid lipids (10%); lycosol (A), broccoli (B), lorbeer tree (C), sesame (D), safflower (E), rice bran (F), pomegranate seeds (G), cranberry (H).	97
4-2-1	Contact angle between surfactant solutions and lipid surface of orange wax and lycopene mixture.	102
4-2-2	Chemical structures of sucrose laurate (A), sucrose palmitate (B), sucrose stearate (C), and lauryl glucoside (D).	103
4-2-3	Particle size of lycopene loaded NLC stabilized by different surfactants.	104
4-2-4	Effect of storage time on ZP of lycopene-loaded NLC stabilized by C-1216 (A) and Plantacare TM 1200 (B).	106
4-2-5	Effect of storage time on particle size of lycopene loaded NLC stabilized by C-1216 (A) and Plantacare TM 1200 (B).	107
4-2-6	Effect of storage time on PDI values of lycopene loaded NLC stabilized by C-1216 (A) and Plantacare TM 1200 (B).	107

- 4-2-7 Stability profiles of lycopene concentration (●) and log concentration (○) in solution (A), C-1216 (B) and Plantacare™ 1200 (C) NLC dispersions. 109
- 4-2-8 Average PCS diameters and PDI values of formulations using three different solid lipid types (orange wax, mango butter and beeswax) during the period of 14 days. 110
- 4-2-9 LD (0.50), LD (0.95) and LD (0.99) diameters of formulations using three different solid lipid types (orange wax, mango butter and beeswax) during the period of 14 days. 111
- 4-2-10 ZP values of formulations using three different solid lipid types (orange wax, mango butter and beeswax) using four different surfactants during the period of 14 days. 111
- 4-2-11 Average PCS diameters and PDI values of formulations after 1, 2, 3, 4 and 5 cycles at 500 bar and 800 bar. 113
- 4-2-12 LD (0.50), LD (0.95) and LD (0.99) diameters of formulations after 1, 2, 3, 4 and 5 cycles at 500 bar and 800 bar. 113
- 4-2-13 Average PCS diameters and PDI values of formulations after 1, 2, 3, 4 and 5 cycles at 500 bar and 800 bar at during the period of 14 days. 114
- 4-2-14 LD (0.50), LD (0.95) and LD (0.99) diameters of formulations after 1, 2, 3, 4 and 5 cycles at 500 bar during the period of 14 days. 115
- 4-2-15 LD (0.50), LD (0.95) and LD (0.99) diameters of formulations after 1, 2, 3, 4 and 5 cycles at 800 bar during the period of 14 days. 115

- 4-2-16 Average PCS diameters and Pdl values of formulations using 116
different liquid lipids; rice bran oil, sesame oil, and pomegranate
seeds oil, stabilized with surfactant combination between Tegocare™
450 and Tween™ 80 at ratio 1:1, respectively.
- 4-2-17 Average PCS diameters and Pdl values of formulations using 117
different liquid lipids; rice bran oil, sesame oil, and pomegranate
seeds oil, stabilized with surfactant combination between Tegocare™
450 and Plantacare™ 1200 at ratio 1:1, respectively.
- 4-2-18 Average PCS diameters and Pdl values of formulations using 118
different liquid lipids; rice bran oil, sesame oil, and pomegranate
seeds oil, stabilized with surfactant combination between Tegocare™
450 and Inutec™ SP1 at ratio 1:1, respectively.
- 4-2-19 LD (0.50), LD (0.95) and LD (0.99) diameters of formulations using 119
different liquid lipids; rice bran oil, sesame oil, and pomegranate
seeds oil, stabilized with surfactant combination between Tegocare™
450 and Inutec™ SP1 at ratio 1:1, respectively.
- 4-2-20 Average PCS diameters and Pdl values of NLC and NE formulations 120
with lycopene and without lycopene.
- 4-2-21 Correlation of antioxidant activities of samples from DPPH (IC₅₀) 123
and ABTS (TEAC) assay.
- 4-2-22 The linear relationship of logarithmic values of IC₅₀ and TEAC. 123

- 4-2-23 The PCS diameters and PDI values of NLC free, NLC load, NE free, and NE load dispersions stored at room temperature at a period of 30 days. 124
- 4-2-24 ZP values of NLC free, NLC load, NE free, and NE load dispersions measured at day 0. 125
- 4-2-25 The chemical structure of PoloxamerTM surfactant. 126
- 4-2-26 Average PCS diameters and the LD (0.50), LD (0.95) and LD (0.99) diameters of formulations using PoloxamerTM 188 and PoloxamerTM 407. 126
- 4-2-27 The chemical structures of sodium stearyl lactylate (DermofeelTM SL) (A) and sodium stearyl glutamate (EumulginTM SG) (B). 128
- 4-2-28 Average PCS diameters and the LD (0.50), LD (0.95) and LD (0.99) diameters of formulations using DermofeelTM SL and EumulginTM SG. 128
- 4-3-1 LM picture (A) and PLM picture (B) of mixture of orange wax 99.9 %w/w and lycopene 0.1 %w/w with magnification of 100x10 folds. 133
- 4-3-2 LM picture (A) and PLM (B) of mixture of orange wax 90 %w/w and rice bran oil 10 %w/w with magnification of 100x10 folds. 134
- 4-3-3 LM picture (A) and PLM picture (B) of mixture of orange wax 89.91 %w/w, rice bran oil 9.99 %w/w, and lycopene 0.1 %w/w with magnification of 100x10 folds. 135

- 4-3-4 LM picture (A) and PLM picture (B) of mixture of orange wax 72 135
%w/w, cholesterol 18 %w/w, rice bran oil 10 %w/w with
magnification of 100x10 folds.
- 4-3-5 LM picture (A) and PLM picture (B) of mixture of orange wax 71.93 136
%w/w, cholesterol 17.98 %w/w, rice bran oil 9.99 %w/w, and
lycopene 0.1 %w/w with magnification of 100x10 folds.
- 4-3-6 The physical appearance of the melted orange wax (A) and orange 137
wax - rice bran oil mixtures containing oil of 10% (B), 20% (C), 30%
(D), 40% (E) and 50% (F).
- 4-3-7 DSC thermograms of the melted orange wax (A) and orange wax - 138
rice oil mixtures containing 10% (B), 20% (C), 30% (D), 40% (E)
and 50% oil (F).
- 4-3-8 Physical appearance of the melted orange wax/cholesterol mixtures 139
of 4:1 (A), 3:1 (B), and 7:3 (C).
- 4-3-9 DSC fusion curves for the mixtures of orange wax and cholesterol at 139
ratios of 4:1 (A) and 3:1 (B), orange wax (C) and cholesterol (D).
- 4-3-10 Outer appearance of Formula 1 (A), Formula 2 (B) and Formula 3 141
(C).
- 4-3-11 The PCS diameters and PDI values of Formula 1 (A), Formula 2 (B) 141
and Formula 3 (C).
- 4-3-12 Outer appearance of Formula 1 (A), Formula 2 (B), and Formula 3 141
(C) after 1 day's storage at room temperature.

4-3-13	DSC thermograms of Formula 4 (A), Formula 5 (B), Formula 6 (C) and Formula 7 (D).	144
4-3-14	The particle size and size distribution of Formula 4 (A), Formula 5 (B), Formula 6 (C) and Formula 7 (D).	147
4-3-15	The particle size and size distribution of the three batches of Formula 4 (A), Formula 5 (B), Formula 6 (C) and Formula 7 (D).	147
4-3-16	Zeta potential of Formula 4 (A), Formula 5 (B), Formula 6 (C) and Formula 7 (D).	148
4-3-17	Particle size and size distribution of Formula 4 (A), Formula 5 (B), Formula 6 (C) and Formula 7 (D) during stored at 25°C for 45 days.	149
4-3-18	Particle size and size distribution of Formula 6 stored at 4°C (A), 25°C (B), and 40°C (C) and Formula 7 stored at 4°C (D), 25°C (E), and 40°C (F).	150
4-3-19	Zeta potential of Formula 6 stored at 4°C (A), 25°C (B), and 40°C (C) and Formula 7 stored at 4°C (D), 25°C (E), and 40°C (F).	151
4-3-20	Effect of temperature on lycopene stability of Formula 6 (A) and Formula 7 (B).	153
4-3-21	The occlusive properties of formula 4, 5, 6, and 7 observed at 6, 24, and 48 h.	155

4-3-22	DSC thermograms of orange wax (A), lycopene (B), melted mixture of orange wax and lycopene (C), melted mixture of orange wax and rice bran oil (D), melted mixture of orange wax, rice bran oil, and lycopene (E), lycopene loaded NE (F), lycopene loaded SLN (G), and lycopene loaded NLC (H).	158
4-3-23	WAXS patterns of orange wax (A), lycopene (B), melted mixture of orange wax and lycopene (C), melted mixture of orange wax and rice bran oil (D), melted mixture of orange wax, rice bran oil, and lycopene (E), lycopene loaded NE (F), lycopene loaded SLN (G), and lycopene loaded NLC (H).	161
4-3-24	ED pattern of NE.	163
4-3-25	ED pattern of SLN.	163
4-3-26	ED pattern of NLC.	164
4-3-27	The bright field cryo-TEM images of lycopene loaded NLC.	165
4-4-1	The outer appearance of the four NLCs obtained.	167
4-4-2	Cumulative amount of lycopene (μg) released from NLC over a period of 24 h independent of using membrane.	170
4-4-3	Cumulative amount of lycopene (μg) released from NLC over a period of 24 h using dialysis membrane.	171
4-4-4	Occlusion factors of NLCs incorporated 0-0.05 %w/w of lycopene observed at 6, 24 and 48 h.	173
4-4-5	Correlation of antioxidant activities of NLC samples from DPPH (IC_{50}) and ABTS (TEAC) assay.	175

4-4-6	Stability profiles of lycopene concentration in NLC dispersions loaded with lycopene 0.005%w/w (A), 0.025% w/w (B) and 0.050% w/w (C).	178
4-5-1	The physical appearance of 7 semisolid cream formulations containing NLC of which the composition of ingredients is detailed in Table 4-5-1.	179
4-5-2	Occlusion factors of base creams and NLC creams of formulation 1 (A), formulation 2 (B), formulation 3 (C), formulation 4 (D), formulation 5 (E), formulation 6 (F) and formulation 7 (G) observed at 6, 24 and 48 h.	183
4-5-3	Stability profiles of lycopene concentration in NLC cream formulation 1 (A), formulation 2 (B), formulation 3 (C), formulation 4 (D), formulation 5 (E), formulation 6 (F) and formulation 7 (G) stored at room temperature.	185
4-5-4	TEAC values of base creams and NLC creams of formulation 1-7.	186
4-5-5	IC ₅₀ values of base creams and NLC creams of formulation 1-7.	187
4-5-6	Correlation of antioxidant activities of base creams and NLC creams from DPPH (IC ₅₀) and ABTS (TEAC) assay.	187


ABBREVIATIONS

ABTS	2,2'-Azinobis (3-ethylbenzothiazoline-6 sulfonic acid)
ACN	Acetonitrile
AUC	Area under the curve
bp	Boiling point
cal	Calorie(s)
CAS	Chemical abstract service
CEVS	Controlled environment vitrification system
CHD	Coronary heart disease
CI%	Percentage of crystallinity index
CMC	Critical micelle concentration
cm ²	square centimeter(s)
cm ³	cubic centimeter(s)
cryo-TEM	Cryogenic transmission electron microscopy
CTFA	Cosmetic, toiletry, and fragrance association
Da	Dalton
DI water	Deionized water
DMSO	Dimethyl sulfoxide
DPPH	2,2-Diphenyl-1-picrylhydrazyl
DSC	Differential scanning calorimetry
ED	Electron diffraction
EE	Entrapment efficiency

e.g.	<i>exempli gratia</i> , “for example”
EM	Electron microscopy
EO	Ethylene oxide
<i>et al</i>	<i>et alii</i> , “and others”
EtOH	Ethanol
FDA	Food and drug administration
g	Gram(s)
GRAS	Generally recognized as safe by the food and drug administration of the USA
HC	Hydrocarbon
HCl	Hydrochloric acid
HDL	High density lipoprotein
HLB	Hydrophilic-lipophilic balance
HPLC	High performance liquid chromatography
IC ₅₀	Inhibition concentration at 50%
i.e.	<i>id est</i> , “that is”
INCI	International Nomenclature of Cosmetic Ingredients
INN	International nonproprietary name
IRI	Imaginary refractive index
J	Joule(s)
kg	Kilogram(s)
L	Liter(s)
LD	Laser diffractometry

LD ₅₀	A dose lethal to 50% of the specified animals or microorganisms
LDA	Laser doppler anemometry
LDL	Low density lipoprotein
LM	Light microscopy
LOD	Lower of detection limit
LOQ	Lower of quantitative
M	Molar
max	Maximum
MeOH	Methanol
mg	Milligram(s)
min	Minute(s) or minimum
mL	milliliter(s)
mM	millimolar
mol	mole(s)
mp	Melting point
MSDS	Material safety data sheet
MW	Molecular weight
NDGA	Nordihydroguaiaretic acid
NE	Nanoemulsion
NLC	Nanostructured lipid carrier
NMF	Natural moisturizing factor
nm	nanometer(s)
o/w	oil-in-water

PBS	Phosphate buffer saline
PCS	Photon correlation spectroscopy
PdI	Polydispersity index
PEG	Polyethylene glycol
PG	Propylene glycol
pH	The negative logarithm of the hydrogen ion concentration
PIDS	Polarization intensity differential scattering
pK _a	The negative logarithm of the dissociation constant
PLM	Polarized light microscopy
RI	Refractive index
ROS	Reactive oxygen species
rpm	Revolutions per minute
s	Second(s)
SAXS	Small angle X-ray scattering
SC	Stratum corneum
SEM	Scanning electron microscopy
SLN	Solid lipid nanoparticle
SPF	Sun protection factor
TEAC	Trolox equivalent antioxidant capacity
TEM	Transmission electron microscopy
TEWL	Transepidermal water loss
THF	Tetrahydrofuran
UV	Ultraviolet
UV/Vis	Ultraviolet/visible

The background of the page features a large, faint watermark of the Chiang Mai University seal. The seal is circular, with the university's name in Thai script at the top and 'CHIANG MAI UNIVERSITY 1964' at the bottom. In the center of the seal is an elephant standing under a five-tiered umbrella.

VLDL	Very low density lipoprotein
WAXS	Wide-angle X-ray scattering
w/o	water-in-oil
w/v	weight in volume
w/w	weight in weight
XRD	X-ray diffractometry
z-ave	Average/mean particle size
ZP	Zeta potential
°C	Degree celsius
μl	Microliter(s)
μM	Micromolar
μg	Microgram(s)
μm	Micrometer(s)

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University
All rights reserved